SynthesisThe oncologist2014
Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification?
Synthesis in The oncologist, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Trial
- Article
- Real-World Practice Patterns in Diagnosis and First-Line Treatment in Metastatic Breast Cancer.The breast journal · 2026Article
- [18 F]-Fluoroestradiol PET (FES-PET) and [18 F] Flurodeoxyglucose PET (FDG-PET) Imaging May Aid in Managing Therapy in Patients with Metastatic Lobular Breast Cancer.Molecular imaging and biology · 2025Article
- Misclassification of second primary and recurrent breast cancer in the surveillance epidemiology and end results registry.Cancer causes & control : CCC · 2025Article
- Bilateral Primary Breast Cancer With Discordance in Molecular Subtypes: A Case Report.International journal of breast cancer · 2025Article
- Receptor discordance after nipple-sparing mastectomy.Surgery in practice and science · 2024Article
- Article
- Evaluation of tumour heterogeneity byBreast cancer research : BCR · 2022Article
- Histologic Discordance Between Primary Tumor and Nodal Metastasis in Breast Cancer: Solving a Clinical Conundrum in the Era of Genomics.The oncologist · 2021Article
- Integrative multiomics-histopathology analysis for breast cancer classification.NPJ breast cancer · 2021Article
- Receptor conversion impacts outcomes of different molecular subtypes of primary breast cancer.Therapeutic advances in medical oncology · 2021Article
- Biomarker heterogeneity between primary breast cancer and synchronous axillary lymph node metastases.Oncology letters · 2020Article
- Efficient Propagation of Circulating Tumor Cells: A First Step for Probing Tumor Metastasis.Cancers · 2020Article
- Article
- Molecular Subtype Discordance in a Young Woman with Synchronous Bilateral Breast Cancer: A Case Report.Cureus · 2020Article
- Mechanisms of resistance to estrogen receptor modulators in ER+/HER2- advanced breast cancer.Cellular and molecular life sciences : CMLS · 2020Review
- The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients.OncoTargets and therapy · 2020Article
- Heterogeneity in Metastatic Breast CancerJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionDiscordance in hormone receptor status has been observed between two breast tumors of the same patients; however, the degree of heterogeneity is debatable with regard to whether it reflects true biological difference or the limited accuracy of receptor assays.
methodsA Bayesian misclassification correction method was applied to data on hormone receptor status of two primary breast cancers from the Surveillance, Epidemiology, and End Results database between 1990 and 2010 and to data on primary breast cancer and paired recurrent/metastatic disease assembled from a meta-analysis of the literature published between 1979 and 2014.
resultsThe sensitivity and specificity of the estrogen receptor (ER) assay were estimated to be 0.971 and 0.920, respectively. After correcting for misclassification, the discordance in ER between two primary breast cancers was estimated to be 1.2% for synchronous ipsilateral pairs, 5.0% for synchronous contralateral pairs, 14.6% for metachronous ipsilateral pairs, and 25.0% for metachronous contralateral pairs. Technical misclassification accounted for 53%-83% of the ER discordance between synchronous primary cancers and 11%-25% of the ER discordance between metachronous cancers. The corrected discordance in ER between primary tumors and recurrent or metastatic lesions was 12.4%, and there were more positive-to-negative changes (10.1%) than negative-to-positive changes (2.3%). Similar patterns were observed for progesterone receptor (PR), although the overall discordance in PR was higher.
conclusionA considerable proportion of discordance in hormone receptor status can be attributed to misclassification in receptor assessment, although the accuracy of receptor assays was excellent. Biopsy of recurrent tumors for receptor retesting should be conducted after considering feasibility, cost, and previous ER/PR status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.